Form 4: REGENXBIO Inc. Executive Steve Pakola Reports Acquisition of 58,386 Shares

Chief Medical Officer Steve Pakola of REGENXBIO Inc. reports acquiring 58,386 shares of common stock on August 1, 2024, through a restricted stock unit award.

Summary

• On August 1, 2024, Steve Pakola, Chief Medical Officer of REGENXBIO Inc., acquired 58,386 shares of common stock.
• The acquisition was made through a time-based restricted stock unit (RSU) award.
• The price per share was $0.00.
• Following the transaction, Pakola directly owns 165,578 shares of REGENXBIO Inc.
• The RSU award vests in four equal installments: 25% on each of February 1, 2025, August 1, 2025, February 1, 2026, and August 1, 2026, contingent upon continuous service to the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by an executive. The vesting schedule suggests a long-term commitment, which is mildly positive.

Positives

• The acquisition of shares by a key executive could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the RSU award indicates a long-term commitment from the executive to the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. This filing indicates changes in beneficial ownership by a key executive at REGENXBIO, which is relevant to investors monitoring insider activity.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the increased stake of a key executive.

Key Dates